multiple sclerosis

Merck of Germany
Pharma

Merck KGaA expects Mavenclad generics to deal serious blow in US

After delivering solid growth in 2025, Germany’s Merck KGaA expects an onslaught of U.S. generics to its MS blockbuster Mavenclad this year.
Fraiser Kansteiner Mar 5, 2026 11:30am
Graham

Roche eyes busy 2026 despite Vabysmo miss, Tecentriq flop

Jan 29, 2026 11:23am
An envelope with rejected mark Vector illustration
Favicon Fierce Biotech

FDA shares CRL for Sanofi MS drug mere weeks after rebuff

Jan 6, 2026 4:30am
Genentech Hidden GeMS campaign

Genentech uncovers 'Hidden GeMS' in latest #MSVisibility drive

Dec 9, 2025 4:05pm
Sandoz

Sandoz's biosimilar to Biogen's Tysabri hits the US after delay

Nov 17, 2025 11:12am
Biogen

Biogen ticks up sales outlook again as MS franchise holds strong

Oct 30, 2025 1:37pm